A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

NCT01287754 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche